The company named Merck KGaA’s Belen Garijo as the successor to Paul Hudson. The change follows a string of clinical setbacks at Sanofi.
The company named Merck KGaA’s Belen Garijo as the successor to Paul Hudson. The change follows a string of clinical setbacks at Sanofi.